Pharma Deals Review, Vol 2003, No 40 (2003)

Font Size:  Small  Medium  Large

Amgen Enters metabolic Disease Market with Biovitrum Deal

Business Review Editor

Abstract


Amgen entered into licensing agreement with Biovitrum to acquire rights to Biovitrum’s small molecule 11-beta-HSD1 enzyme inhibitor. The lead product in the 11-beta-HSD1 enzyme inhibitor program is BVT.3498, which is in phase IIa clinical trials for treating type II diabetes.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.